[go: up one dir, main page]

MX2019007772A - Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de sequedad vaginal y disfuncion sexual en mujeres post-menopausicas. - Google Patents

Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de sequedad vaginal y disfuncion sexual en mujeres post-menopausicas.

Info

Publication number
MX2019007772A
MX2019007772A MX2019007772A MX2019007772A MX2019007772A MX 2019007772 A MX2019007772 A MX 2019007772A MX 2019007772 A MX2019007772 A MX 2019007772A MX 2019007772 A MX2019007772 A MX 2019007772A MX 2019007772 A MX2019007772 A MX 2019007772A
Authority
MX
Mexico
Prior art keywords
disclosed
vaginal
administration
lodoxifene
arzoxifene
Prior art date
Application number
MX2019007772A
Other languages
English (en)
Inventor
Labrie Fernand
El-Alfy Mohamed
Berger Louise
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of MX2019007772A publication Critical patent/MX2019007772A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Métodos novedosos para tratar o reducir la probabilidad de adquirir disfunciones vaginales, más particularmente resequedad vaginal y dispareunia, que conducen a la disfunción sexual y a un bajo deseo y rendimiento sexual, en animales susceptibles, de sangre caliente incluyendo humanos, que involucra la administración de un precursor esteroide sexual. La administración adicional de estrógeno o modulador receptor de estrógeno selectivo, particularmente aquéllos seleccionados del grupo que consiste de Raloxifeno, Arzoxifeno, Tamoxifén, Droloxifeno, Toremifeno, Yodoxifeno, GW 5638, TSE- 424, ERA-923, y lasofoxifeno, y muy particularmente compuestos que tienen la estructura general: (Ver fórmula) se describen específicamente para el tratamiento médico y o inhibición de desarrollo de algunas de estas enfermedades anteriormente mencionadas. También se describen composiciones farmacéuticas para el suministro de ingrediente(s) activo(s) y kit(s) útiles para la invención.
MX2019007772A 2004-10-20 2007-04-20 Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de sequedad vaginal y disfuncion sexual en mujeres post-menopausicas. MX2019007772A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62045204P 2004-10-20 2004-10-20

Publications (1)

Publication Number Publication Date
MX2019007772A true MX2019007772A (es) 2019-09-09

Family

ID=36202646

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2013009022A MX368189B (es) 2004-10-20 2005-10-20 Precursores esteroides sexuales solos o en combinación con un modulador receptor de estrógeno selectivo y/o con estrógenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevención y tratamiento de sequedad vaginal y disfunción sexual en mujeres post-menopáusicas.
MX2007004830A MX2007004830A (es) 2004-10-20 2005-10-20 Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de resequedad vaginal y disfuncion sexu
MX2019007772A MX2019007772A (es) 2004-10-20 2007-04-20 Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de sequedad vaginal y disfuncion sexual en mujeres post-menopausicas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2013009022A MX368189B (es) 2004-10-20 2005-10-20 Precursores esteroides sexuales solos o en combinación con un modulador receptor de estrógeno selectivo y/o con estrógenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevención y tratamiento de sequedad vaginal y disfunción sexual en mujeres post-menopáusicas.
MX2007004830A MX2007004830A (es) 2004-10-20 2005-10-20 Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de resequedad vaginal y disfuncion sexu

Country Status (27)

Country Link
US (3) US8835413B2 (es)
EP (1) EP1802312B1 (es)
JP (3) JP5057983B2 (es)
KR (1) KR20070067235A (es)
CN (5) CN101106999B (es)
AP (1) AP2365A (es)
AU (1) AU2005297367B2 (es)
BR (1) BRPI0516243C1 (es)
CA (2) CA2749235C (es)
DK (1) DK1802312T3 (es)
EA (1) EA014878B1 (es)
ES (1) ES2553101T3 (es)
GE (1) GEP20105066B (es)
HK (1) HK1225629A1 (es)
HR (1) HRP20070169B1 (es)
HU (1) HUE025651T2 (es)
IL (3) IL182633A (es)
MA (1) MA29018B1 (es)
MX (3) MX368189B (es)
NO (1) NO340123B1 (es)
NZ (1) NZ554619A (es)
RS (1) RS20070166A (es)
SG (2) SG155258A1 (es)
TN (1) TNSN07147A1 (es)
UA (1) UA93985C2 (es)
WO (1) WO2006042409A1 (es)
ZA (1) ZA200703198B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
JP5057983B2 (ja) 2004-10-20 2012-10-24 アンドルシェルシュ・インコーポレイテッド 閉経後の女性における膣乾燥および性機能障害の予防および処置のための性ステロイド前駆体単独あるいは選択的エストロゲン受容体モジュレータならびに／またはエストロゲン類および／もしくは５型ｃＧＭＰホスホジエステラーゼ阻害剤の併用
EP2034984A4 (en) * 2006-06-02 2013-03-06 Pear Tree Women S Health Care PROCESS FOR TREATING ATROPHIC VAGINITIS
WO2008157335A2 (en) 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
EP2011496A1 (en) * 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
JP2013528223A (ja) 2010-06-10 2013-07-08 アラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその用途
AU2011267798B2 (en) 2010-06-16 2015-04-02 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
WO2013012430A1 (en) * 2011-07-19 2013-01-24 Riepl Michael S Dhea bioadhesive controlled release gel
US9320744B2 (en) 2011-10-19 2016-04-26 Dhea Llc DHEA bioadhesive controlled release gel
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
BR112018011483A2 (pt) * 2015-12-07 2018-12-04 Therapeuticsmd Inc métodos e composições farmacêuticas com estradiol vaginalmente inserido
SG10201913951YA (en) 2016-10-11 2020-03-30 Univ Duke Lasofoxifene treatment of er+ breast cancer
US20190231743A1 (en) * 2016-10-11 2019-08-01 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
RU2636619C1 (ru) * 2017-02-20 2017-11-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения вагинальной атрофии у женщин в постменопаузе с учетом состояния эпителия и микробиоценоза влагалища
US11497730B2 (en) 2018-04-10 2022-11-15 Duke University Lasofoxifene treatment of breast cancer
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11690852B2 (en) 2020-12-01 2023-07-04 Endorecherche. Inc. Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN117924262A (zh) * 2022-10-14 2024-04-26 中国科学院上海药物研究所 二氢苯并噻喃类衍生物及其制备方法和用途

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104924A (ja) 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
US4835147A (en) 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5407684A (en) 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5246704A (en) 1989-01-23 1993-09-21 Kanebo, Ltd. Vaginal suppository
AU5281990A (en) 1989-03-10 1990-10-09 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
EP0595796B1 (en) 1989-07-07 2003-01-15 Endorecherche Inc. Method of treatment of androgen-related diseases
DK0943328T3 (da) 1989-07-07 2004-10-18 Endorech Inc Kombinationsterapi til profylakse og/eller behandling af godartet prostatahyperplasi
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
PT1382340E (pt) * 1993-01-19 2006-07-31 Endorech Inc Utilizacoes terapeuticas de desidroepiandrosterona para tratar libido diminuida e osteoporose
JP2698865B2 (ja) 1994-08-08 1998-01-19 仲昭 大澤 筋緊張性ジストロフィー症治療剤
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
JP2000506505A (ja) 1996-01-11 2000-05-30 ノボ ノルディスク アクティーゼルスカブ 閉経期の症状の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
CZ217198A3 (cs) 1996-01-11 1998-11-11 Novo Nordisk A/S Použití L-enantiomeru centochromanu pro výrobu farmaceutického prostředku
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
SK281737B6 (sk) 1996-04-19 2001-07-10 American Home Products Corporation 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
WO1999021562A1 (en) 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6013665A (en) 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CA2334702C (en) * 1998-06-11 2005-10-18 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol
US6007824A (en) 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US20030181353A1 (en) 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
PE20010404A1 (es) 1999-06-11 2001-04-09 Watson Pharmaceuticals Inc Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US7452545B2 (en) 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
US20050245494A1 (en) 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20020165429A1 (en) 1999-07-01 2002-11-07 40 J's Llc Clitoral sensitizing arrangements
US20070042060A1 (en) 1999-07-01 2007-02-22 Thompson Ronald J Methods to treat one or all of the defined etiologies of female sexual Dysfunction
DE60043305D1 (de) * 1999-07-06 2009-12-24 Endorech Inc Pharmazeutische zubereitungen zur behandlung von insulinresitenz
HUP0204211A3 (en) * 2000-01-28 2005-06-28 Endorech Inc Sainte Foy Selective estrogen receptor modulators in combination with estrogens and pharmaceutical compositions containing them
US6614831B2 (en) * 2000-02-10 2003-09-02 Process Technology International, Inc. Mounting arrangement for auxiliary burner or lance
CN1315718A (zh) * 2000-03-24 2001-10-03 周广胜 一种中字格对称习字法
US20020022052A1 (en) 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
JP2002024098A (ja) * 2000-07-04 2002-01-25 Canon Inc 情報処理装置、情報処理システム、情報処理方法及び記録媒体
EP1356438B1 (en) * 2000-07-10 2014-06-18 PayPal, Inc. System and method for verifying a financial instrument
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
KR20100036390A (ko) * 2001-03-06 2010-04-07 셀러지 파마세우티칼스, 인크 비뇨생식기 장애 치료용 화합물 및 그 방법
AU2002303427A1 (en) 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
US20030216329A1 (en) 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
AU2002303425A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
JP3533664B2 (ja) * 2001-06-27 2004-05-31 ソニー株式会社 負極材料およびそれを用いた電池
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
FR2828100B1 (fr) 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7348352B2 (en) 2001-10-23 2008-03-25 Bioresponse L.L.C. Diindolylmethane for the treatment of HPV infection
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US6809079B2 (en) * 2002-01-08 2004-10-26 Vasogenix Pharmaceuticals, Inc. Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
WO2003086291A2 (en) 2002-04-10 2003-10-23 Yu Ruey J Urea compositions
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20060018937A1 (en) 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20050020552A1 (en) 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
JP4866740B2 (ja) 2004-01-07 2012-02-01 アンドルシェルシュ・インコーポレイテッド へリックス１２指向ステロイド系医薬品
US20050181057A1 (en) 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20080119445A1 (en) 2004-09-08 2008-05-22 Woodward John R Methods of female sexual enhancement
US20060252734A1 (en) 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
US20060276442A1 (en) 2004-09-08 2006-12-07 Woodward John R Methods of female sexual enhancement
JP5057983B2 (ja) 2004-10-20 2012-10-24 アンドルシェルシュ・インコーポレイテッド 閉経後の女性における膣乾燥および性機能障害の予防および処置のための性ステロイド前駆体単独あるいは選択的エストロゲン受容体モジュレータならびに／またはエストロゲン類および／もしくは５型ｃＧＭＰホスホジエステラーゼ阻害剤の併用
KR20070073964A (ko) 2004-11-01 2007-07-10 앙도르쉐르슈 인코포레이티드 피부 노화 치료용 또는 피부 노화의 획득 가능성감소용으로서의 안드로겐의 용도
EP1904028A1 (en) 2005-06-16 2008-04-02 Warner Chilcott Company Inc. Estrogen compositions for vaginal administration
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
JP4179624B2 (ja) 2006-07-18 2008-11-12 ヒロセ電機株式会社 平型導体用電気コネクタ
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
JP5373931B2 (ja) * 2012-03-22 2013-12-18 日本電信電話株式会社 仮想視点画像生成方法，仮想視点画像生成装置および仮想視点画像生成プログラム

Also Published As

Publication number Publication date
RS20070166A (sr) 2008-09-29
CN101106999B (zh) 2017-06-09
JP5653965B2 (ja) 2015-01-14
EA200700893A1 (ru) 2007-10-26
CN102357248A (zh) 2012-02-22
US20070270394A1 (en) 2007-11-22
EP1802312B1 (en) 2015-09-16
IL249633A0 (en) 2017-02-28
WO2006042409A1 (en) 2006-04-27
HUE025651T2 (en) 2016-04-28
CA2749235A1 (en) 2006-04-27
CN106038572A (zh) 2016-10-26
BRPI0516243B1 (pt) 2020-08-11
JP5057983B2 (ja) 2012-10-24
HRP20070169A2 (en) 2007-09-30
CN101106999A (zh) 2008-01-16
BRPI0516243B8 (pt) 2021-02-23
CN106138065A (zh) 2016-11-23
US8835413B2 (en) 2014-09-16
CN102406650A (zh) 2012-04-11
DK1802312T3 (en) 2015-12-14
ZA200703198B (en) 2008-09-25
US10478443B2 (en) 2019-11-19
JP2012162578A (ja) 2012-08-30
NZ554619A (en) 2011-01-28
US10076525B2 (en) 2018-09-18
CA2584524C (en) 2012-02-07
CA2584524A1 (en) 2006-04-27
US20180271880A1 (en) 2018-09-27
TNSN07147A1 (fr) 2008-11-21
MX368189B (es) 2019-09-23
AU2005297367B2 (en) 2010-02-04
NO20072518L (no) 2007-07-19
EP1802312A1 (en) 2007-07-04
IL182633A (en) 2017-01-31
EP1802312A4 (en) 2009-02-18
HRP20070169B1 (hr) 2020-07-10
AP2007003970A0 (en) 2007-04-30
IL246698B (en) 2021-07-29
AP2365A (en) 2012-02-20
IL182633A0 (en) 2007-09-20
CA2749235C (en) 2014-08-12
GEP20105066B (en) 2010-08-25
BRPI0516243C1 (pt) 2021-05-25
MX2007004830A (es) 2007-10-04
NO340123B1 (no) 2017-03-13
SG10201404796QA (en) 2014-10-30
IL246698A0 (en) 2016-08-31
BRPI0516243A (pt) 2008-08-26
JP2008516995A (ja) 2008-05-22
EA014878B1 (ru) 2011-02-28
JP2012162579A (ja) 2012-08-30
UA93985C2 (ru) 2011-03-25
ES2553101T3 (es) 2015-12-04
SG155258A1 (en) 2009-09-30
AU2005297367A1 (en) 2006-04-27
MA29018B1 (fr) 2007-11-01
HK1225629A1 (zh) 2017-09-15
IL249633B (en) 2019-06-30
US20160058774A1 (en) 2016-03-03
KR20070067235A (ko) 2007-06-27

Similar Documents

Publication Publication Date Title
MX2019007772A (es) Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de sequedad vaginal y disfuncion sexual en mujeres post-menopausicas.
CA2050291C (en) Combination therapy for the treatment of estrogen sensitive diseases
AU643445B2 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
MXPA02008770A (es) Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina.
IE902458A1 (en) Method of treatment of androgen-related diseases
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
TW200728289A (en) Non-basic melanin concentrating hormone receptor-1 antagonists
EP0483077A2 (en) A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas.
JP2006503850A5 (es)
JP2003532640A (ja) アポモルヒネ誘導体及びその使用方法
CN1262622A (zh) 调节人性反应的联合治疗
KR101072175B1 (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 배뇨장애 치료제 및 부종 치료제조성물
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
CA2605796A1 (en) Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
RU2010115647A (ru) Композиция и способ лечения или профилактики доброкачественной гиперплазии предстательной железы и симптомов со стороны нижних отделов мочевыводящих путей
JP5061109B2 (ja) 抗性腺刺激剤としての９，１１−コルテキソロンのＣ３−Ｃ１０１７α−エステル類
MXPA99010400A (es) Terapia en combinacion para modular la respuestasexual humana